Subba R Katamreddy, Ph.D. (K.S.Reddy), the founder and president of V-PHARMA, has over 16 years of synthetic organic chemistry and preclinical drug discovery experience in both academia and the pharmaceutical industry. Dr. K.S.Reddy earned his Ph.D. in Chemistry in 1995 at the Pondicherry University, Pondicherry, India. Over the next five years, he completed his postdoctoral studies at the University of Hyderabad, India; the University of Barcelona, Spain; and the Emory University in Atlanta, GA, USA. He then joined GlaxoSmithKline as a principal scientist in the department of medicinal chemistry in 2001 and progressed to be named and served as a Research Investigator. Later, in 2009, he founded V-PHARMA.
Dr. K.S. Reddy has worked in preclinical drug discovery programs with multidisciplinary teams consisting of representatives from Chemistry, Biology, Pharmacology, Cheminformatics, and Legal. He has experience working on multiple target classes such as nuclear receptors (NRs), Opioids, and GPCR’s. Dr. K.S.Reddy developed significant expertise in discovering high-quality clinical candidates by integrating currently available drug discovery principles/tools and addressing complex developmental issues such as solubility, bioavailability, and securing intellectual property rights. This effort ultimately helped in identifying two phases II clinical assets.
He is a co-inventor of 12 patents/patent applications and co-authored 26 research articles published in peer-reviewed journals. He is the recipient of several fellowships and awards; including the Junior and Senior Research Fellowships from UGC, India, Research Associateships from CSIR, India, and Spain. He won GlaxoSmithKline R&D’s Exceptional Science Award in 2007 for his creative work on the GPR119 agonist drug discovery program (to treat metabolic disorders including Type-2 diabetes).
Dr. K.S.Reddy is a member of the American Chemical Society (ACS), ACS Medicinal Chemistry, the America Diabetes Association (ADA), and the New York Academy of Sciences (NYAS).